Table 2. Outcomes in Major Clinical Trials for Atogepant.

OD: Once daily, BID: Twice daily, SD - Single Dose, CFB change from baseline, MMDs monthly migraine days, MHDs monthly headache days, TRAEs treatment-related adverse events, SAEs serious adverse events, OR odds ratio, CI confidence interval*p <0.05, **p<0.001, vs. placebo; ^aThe data are presented as difference from Placebo

Study	Doses	CFB in MMDs after 12 weeks (95% CI)a	CFB in MHDs after 12 weeks (95% CI)a	≥ 50% reduction in MMDs (%) (OR, 95% CI)	CFB in acute medication use days (95% CI)a	Incidence of TRAEs (%)	Incidence of SAEs (%)	Drug discontinuation rate (%)
Ankrom et al.9	60 mg OD	-	-	-	-	23.3	0	15.3
Goadsby et al.10	10 mg OD	− 1.2* (− 1.9 to − 0.4)	− 1.4* (− 2.2 to – 0.5)	1.5 (1 to 2.3)	− 1.3 (− 2.0 to − 0.6)	18	0	4
	30 mg OD	− 0.9* (− 1.6 to − 0.3)	− 1.2* (− 1.9 to − 0.6	1.5 (1 to 2.1)	− 1.4 (− 2.0 to − 0.9)	21	0	6
	60 mg OD	− 0.7* (− 1.4 to − 0.1)	− 0.9* (− 1.6 to − 0.2)	1.4 (1 to 2)	− 1.1 (− 1.7 to − 0.5)	23	0	3
	30 mg BID	− 1.4* (− 2.2 to − 0.6)	− 1.3* (− 2.2 to − 0.4)	1.8* (1.2 to 2.9)	− 1.4* (− 2.1 to − 0.6)	21	0	6
	60 mg BID	− 1.3* (− 2.1 to − 0.5)	− 1.4* (− 2.3 to − 0.5)	2.0* (1.3 to 3.2)	− 1.2* (− 1.9 to − 0.5)	26	0	8
	Placebo	-	-	-	-	16	0	3
Min et al.11	170 mg OD	-	-	-	-	87	0	8.7
	Placebo	-	-	-	-	72.7	0	0
Boinpally et al.12	300 mg SD	-	-	-	-	1.7	0	0
	Placebo	-	-	-	-	-	-	-
Ailani et al.13, Schwedt et al.14, and Lipton et al.15	10 mg OD	− 1.2** (− 1.8 to − 0.6)	− 1.4** (− 2.0 to − 0.8)	3.1** (2 to 4.6)	− 1.3** (− 1.8 to − 0.8)	23.1	0.5	4.1
	30 mg OD	− 1.9** (− 1.9 to –0.8)	− 1.5** (− 2.1 to− 1.1)	3.5** (2. 4 to 5.3)	− 1.3** (− 1.8 to − 0.8)	14.9	0	1.8
	60 mg OD	− 1.7** (− 2.3 to − 1.2)	− 1.7** (− 2.3 to − 1.1)	3.8** (2.6 to 5.7)	− 1.5** (− 2.0 to − 1.0)	19.5	0	2.6
	Placebo	-	-	-	-	9	0	2.7
Klein et al.16	60 mg OD	-	-	-	-	8.8	3.4	25.4 (after open label treatment period) and 27.7 (at safety follow-up period)
Ashina et al.17	60 mg OD	-	-	84.2	-	18	4.4	31.6
	Placebo	-	-	-	-	36.2	3.6	31.2